menu search

ABIO / ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study

ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study
ARCA biopharma IncĀ (NASDAQ: ABIO) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19. In the 160-patient trial, both doses of rNAPc2 demonstrated a treatment benefit. Read More
Posted: Apr 1 2022, 07:21
Author Name: Benzinga
Views: 110819

ABIO News  

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

By Seeking Alpha
May 3, 2022

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

Activist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Subsequently, management has started a strategic review. more_horizontal

ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study

By Benzinga
April 1, 2022

ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study

ARCA biopharma IncĀ (NASDAQ: ABIO) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor, a more_horizontal


Search within

Pages Search Results: